Skip to main content
Erschienen in: Wiener klinische Wochenschrift 15-16/2015

01.08.2015 | review article

Tuberous Sclerosis Complex: new criteria for diagnostic work-up and management

verfasst von: Sharon Samueli, Klaus Abraham, Anastasia Dressler, Gudrun Groeppel, Constanze Jonak, Angelika Muehlebner, Daniela Prayer, Andreas Reitner, Univ. Prof. Dr. Martha Feucht, Pädiatrisches TSC-Zentrum Wien

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 15-16/2015

Einloggen, um Zugang zu erhalten

Summary

Tuberous sclerosis complex (TSC) is a rare genetic multisystem disorder, characterized by predominantly benign tumors in potentially all organ systems. System involvement, severity of clinical symptoms and the response to treatment are age-dependent and heterogeneous. Consequently, the disorder is still not recognized in a considerable number of patients. The diagnostic criteria and the guidelines for surveillance and management of patients with TSC were revised, and the establishment of specialized TSC-centers was strongly recommended during an International Consensus Conference in 2012. TOSCA (TuberOus SClerosis registry to increase disease Awareness), an international patient registry, was started to allow new insights into the causes of different courses. Finally, there are—since the approval of the mTOR inhibitor Everolimus—promising new therapeutic approaches.
This review focuses on the various TSC related symptoms occurring at different ages, the novel recommendations for diagnosis and treatment as well as the need for multidisciplinary follow-up.
Literatur
1.
Zurück zum Zitat van Slegtenhorst M, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 1997;277(5327):805–8.CrossRefPubMed van Slegtenhorst M, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 1997;277(5327):805–8.CrossRefPubMed
2.
Zurück zum Zitat European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 1993;75(7):1305–15.CrossRef European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 1993;75(7):1305–15.CrossRef
3.
Zurück zum Zitat Dabora SL, et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet. 2001;68(1):64–80.PubMedCentralCrossRefPubMed Dabora SL, et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet. 2001;68(1):64–80.PubMedCentralCrossRefPubMed
4.
Zurück zum Zitat Jones AC, et al. Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. Am J Hum Genet. 1999;64(5):1305–15.PubMedCentralCrossRefPubMed Jones AC, et al. Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. Am J Hum Genet. 1999;64(5):1305–15.PubMedCentralCrossRefPubMed
5.
Zurück zum Zitat Lasarge CL, Danzer SC. Mechanisms regulating neuronal excitability and seizure development following mTOR pathway hyperactivation. Front Mol Neurosci. 2014;7:18. Lasarge CL, Danzer SC. Mechanisms regulating neuronal excitability and seizure development following mTOR pathway hyperactivation. Front Mol Neurosci. 2014;7:18.
6.
Zurück zum Zitat Tee AR, et al. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A. 2002;99(21):13571–6.PubMedCentralCrossRefPubMed Tee AR, et al. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A. 2002;99(21):13571–6.PubMedCentralCrossRefPubMed
7.
Zurück zum Zitat O’Callaghan FJ, et al. Prevalence of tuberous sclerosis estimated by capture-recapture analysis. Lancet. 1998;351(9114):1490.CrossRefPubMed O’Callaghan FJ, et al. Prevalence of tuberous sclerosis estimated by capture-recapture analysis. Lancet. 1998;351(9114):1490.CrossRefPubMed
8.
9.
Zurück zum Zitat Bader RS, et al. Fetal rhabdomyoma: prenatal diagnosis, clinical outcome, and incidence of associated tuberous sclerosis complex. J Pediatr. 2003;143(5):620–4.CrossRefPubMed Bader RS, et al. Fetal rhabdomyoma: prenatal diagnosis, clinical outcome, and incidence of associated tuberous sclerosis complex. J Pediatr. 2003;143(5):620–4.CrossRefPubMed
10.
Zurück zum Zitat Jozwiak S, et al. Clinical and genotype studies of cardiac tumors in 154 patients with tuberous sclerosis complex. Pediatrics. 2006;118(4):e1146–51.CrossRefPubMed Jozwiak S, et al. Clinical and genotype studies of cardiac tumors in 154 patients with tuberous sclerosis complex. Pediatrics. 2006;118(4):e1146–51.CrossRefPubMed
11.
Zurück zum Zitat Rovira A, et al. Recommendations for the radiological diagnosis and follow-up of neuropathological abnormalities associated with tuberous sclerosis complex. J Neurooncol. 2014;118(2):205–23.CrossRefPubMed Rovira A, et al. Recommendations for the radiological diagnosis and follow-up of neuropathological abnormalities associated with tuberous sclerosis complex. J Neurooncol. 2014;118(2):205–23.CrossRefPubMed
12.
Zurück zum Zitat van Eeghen AM, et al. The neuroanatomical phenotype of tuberous sclerosis complex: focus on radial migration lines. Neuroradiology. 2013;55(8):1007–14.CrossRefPubMed van Eeghen AM, et al. The neuroanatomical phenotype of tuberous sclerosis complex: focus on radial migration lines. Neuroradiology. 2013;55(8):1007–14.CrossRefPubMed
14.
Zurück zum Zitat Jozwiak S, et al. Usefulness of diagnostic criteria of tuberous sclerosis complex in pediatric patients. J Child Neurol. 2000;15(10):652–9.CrossRefPubMed Jozwiak S, et al. Usefulness of diagnostic criteria of tuberous sclerosis complex in pediatric patients. J Child Neurol. 2000;15(10):652–9.CrossRefPubMed
15.
Zurück zum Zitat O’Callaghan FJ, et al. The relation of infantile spasms, tubers, and intelligence in tuberous sclerosis complex. Arch Dis Child. 2004;89(6):530–3.PubMedCentralCrossRefPubMed O’Callaghan FJ, et al. The relation of infantile spasms, tubers, and intelligence in tuberous sclerosis complex. Arch Dis Child. 2004;89(6):530–3.PubMedCentralCrossRefPubMed
16.
Zurück zum Zitat Curatolo P, et al. Infantile spasms in tuberous sclerosis complex. Brain Dev. 2001;23(7):502–7.CrossRefPubMed Curatolo P, et al. Infantile spasms in tuberous sclerosis complex. Brain Dev. 2001;23(7):502–7.CrossRefPubMed
17.
Zurück zum Zitat Cusmai R, et al. Long-term neurological outcome in children with early-onset epilepsy associated with tuberous sclerosis. Epilepsy Behav. 2011;22(4):735–9.CrossRefPubMed Cusmai R, et al. Long-term neurological outcome in children with early-onset epilepsy associated with tuberous sclerosis. Epilepsy Behav. 2011;22(4):735–9.CrossRefPubMed
18.
Zurück zum Zitat de Vries P, et al. Consensus clinical guidelines for the assessment of cognitive and behavioural problems in Tuberous Sclerosis. Eur Child Adolesc Psychiatry. 2005;14(4):183–90.CrossRefPubMed de Vries P, et al. Consensus clinical guidelines for the assessment of cognitive and behavioural problems in Tuberous Sclerosis. Eur Child Adolesc Psychiatry. 2005;14(4):183–90.CrossRefPubMed
19.
Zurück zum Zitat Jozwiak S, Nabbout R, Curatolo P. Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): clinical recommendations. Eur J Paediatr Neurol. 2013;17(4):348–52.CrossRefPubMed Jozwiak S, Nabbout R, Curatolo P. Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): clinical recommendations. Eur J Paediatr Neurol. 2013;17(4):348–52.CrossRefPubMed
20.
Zurück zum Zitat Franz DN, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013;381(9861):125–32.CrossRefPubMed Franz DN, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013;381(9861):125–32.CrossRefPubMed
21.
Zurück zum Zitat Riikonen R. Recent advances in the pharmacotherapy of infantile spasms. CNS Drugs. 2014;28(4):279–90.CrossRefPubMed Riikonen R. Recent advances in the pharmacotherapy of infantile spasms. CNS Drugs. 2014;28(4):279–90.CrossRefPubMed
22.
Zurück zum Zitat Jones K, et al. Adrenocorticotropic Hormone Versus Prednisolone in the Treatment of Infantile Spasms Post Vigabatrin Failure. J Child Neurol. 2014 Jun 25. pii: 0883073814533148. Epub ahead of print. Jones K, et al. Adrenocorticotropic Hormone Versus Prednisolone in the Treatment of Infantile Spasms Post Vigabatrin Failure. J Child Neurol. 2014 Jun 25. pii: 0883073814533148. Epub ahead of print.
23.
Zurück zum Zitat Jansen FE, et al. Epilepsy surgery in tuberous sclerosis: a systematic review. Epilepsia. 2007;48(8):1477–84.CrossRefPubMed Jansen FE, et al. Epilepsy surgery in tuberous sclerosis: a systematic review. Epilepsia. 2007;48(8):1477–84.CrossRefPubMed
24.
Zurück zum Zitat Jansen FE, et al. Epilepsy surgery in tuberous sclerosis: the Dutch experience. Seizure. 2007;16(5):445–53.CrossRefPubMed Jansen FE, et al. Epilepsy surgery in tuberous sclerosis: the Dutch experience. Seizure. 2007;16(5):445–53.CrossRefPubMed
25.
Zurück zum Zitat Domanska-Pakiela D, et al. EEG abnormalities preceding the epilepsy onset in tuberous sclerosis complex patients-A prospective study of 5 patients. Eur J Paediatr Neurol. 2014;18(4):458–68.CrossRefPubMed Domanska-Pakiela D, et al. EEG abnormalities preceding the epilepsy onset in tuberous sclerosis complex patients-A prospective study of 5 patients. Eur J Paediatr Neurol. 2014;18(4):458–68.CrossRefPubMed
26.
Zurück zum Zitat Robertson DM. Ophthalmic manifestations of tuberous sclerosis. Ann N Y Acad Sci. 1991;615:17–25.CrossRefPubMed Robertson DM. Ophthalmic manifestations of tuberous sclerosis. Ann N Y Acad Sci. 1991;615:17–25.CrossRefPubMed
27.
Zurück zum Zitat Rowley SA, O’Callaghan FJ, Osborne JP. Ophthalmic manifestations of tuberous sclerosis: a population based study. Br J Ophthalmol. 2001;85(4):420–3.PubMedCentralCrossRefPubMed Rowley SA, O’Callaghan FJ, Osborne JP. Ophthalmic manifestations of tuberous sclerosis: a population based study. Br J Ophthalmol. 2001;85(4):420–3.PubMedCentralCrossRefPubMed
28.
Zurück zum Zitat Franz DN. Non-neurologic manifestations of tuberous sclerosis complex. J Child Neurol. 2004;19(9):690–8.PubMed Franz DN. Non-neurologic manifestations of tuberous sclerosis complex. J Child Neurol. 2004;19(9):690–8.PubMed
29.
Zurück zum Zitat Mennel S, et al. Current treatment modalities for exudative retinal hamartomas secondary to tuberous sclerosis: review of the literature. Acta Ophthalmol Scand. 2007;85(2):127–32.CrossRefPubMed Mennel S, et al. Current treatment modalities for exudative retinal hamartomas secondary to tuberous sclerosis: review of the literature. Acta Ophthalmol Scand. 2007;85(2):127–32.CrossRefPubMed
30.
Zurück zum Zitat Au KS, et al. Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States. Genet Med. 2007;9(2):88–100.CrossRefPubMed Au KS, et al. Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States. Genet Med. 2007;9(2):88–100.CrossRefPubMed
31.
Zurück zum Zitat Datta AN, Hahn CD, Sahin M. Clinical presentation and diagnosis of tuberous sclerosis complex in infancy. J Child Neurol. 2008;23(3):268–73.CrossRefPubMed Datta AN, Hahn CD, Sahin M. Clinical presentation and diagnosis of tuberous sclerosis complex in infancy. J Child Neurol. 2008;23(3):268–73.CrossRefPubMed
32.
Zurück zum Zitat Jozwiak S, et al. Skin lesions in children with tuberous sclerosis complex: their prevalence, natural course, and diagnostic significance. Int J Dermatol. 1998;37(12):911–7.CrossRefPubMed Jozwiak S, et al. Skin lesions in children with tuberous sclerosis complex: their prevalence, natural course, and diagnostic significance. Int J Dermatol. 1998;37(12):911–7.CrossRefPubMed
33.
Zurück zum Zitat Staley BA, Vail EA, Thiele EA. Tuberous sclerosis complex: diagnostic challenges, presenting symptoms, and commonly missed signs. Pediatrics. 2011;127(1):e117–25.PubMedCentralCrossRefPubMed Staley BA, Vail EA, Thiele EA. Tuberous sclerosis complex: diagnostic challenges, presenting symptoms, and commonly missed signs. Pediatrics. 2011;127(1):e117–25.PubMedCentralCrossRefPubMed
34.
Zurück zum Zitat Yates JR, et al. The Tuberous Sclerosis 2000 Study: presentation, initial assessments and implications for diagnosis and management. Arch Dis Child. 2011;96(11):1020–5.CrossRefPubMed Yates JR, et al. The Tuberous Sclerosis 2000 Study: presentation, initial assessments and implications for diagnosis and management. Arch Dis Child. 2011;96(11):1020–5.CrossRefPubMed
35.
Zurück zum Zitat Webb DW, et al. The cutaneous features of tuberous sclerosis: a population study. Br J Dermatol. 1996;135(1):1–5.CrossRefPubMed Webb DW, et al. The cutaneous features of tuberous sclerosis: a population study. Br J Dermatol. 1996;135(1):1–5.CrossRefPubMed
36.
Zurück zum Zitat Northrup H, Krueger DA. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr Neurol. 2013;49(4):243–54.PubMedCentralCrossRefPubMed Northrup H, Krueger DA. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr Neurol. 2013;49(4):243–54.PubMedCentralCrossRefPubMed
37.
Zurück zum Zitat Tyburczy ME, et al. Sun exposure causes somatic second-hit mutations and angiofibroma development in tuberous sclerosis complex. Hum Mol Genet. 2014;23(8):2023–9.PubMedCentralCrossRefPubMed Tyburczy ME, et al. Sun exposure causes somatic second-hit mutations and angiofibroma development in tuberous sclerosis complex. Hum Mol Genet. 2014;23(8):2023–9.PubMedCentralCrossRefPubMed
38.
Zurück zum Zitat Foster RS, Bint LJ, Halbert AR. Topical 0.1 % rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients. Australas J Dermatol. 2012;53(1):52–6.CrossRefPubMed Foster RS, Bint LJ, Halbert AR. Topical 0.1 % rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients. Australas J Dermatol. 2012;53(1):52–6.CrossRefPubMed
39.
Zurück zum Zitat Wataya-Kaneda M, et al. A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity. Br J Dermatol. 2011;165(4):912–6.CrossRefPubMed Wataya-Kaneda M, et al. A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity. Br J Dermatol. 2011;165(4):912–6.CrossRefPubMed
40.
Zurück zum Zitat Shepherd CW, et al. Causes of death in patients with tuberous sclerosis. Mayo Clin Proc. 1991;66(8):792–6.CrossRefPubMed Shepherd CW, et al. Causes of death in patients with tuberous sclerosis. Mayo Clin Proc. 1991;66(8):792–6.CrossRefPubMed
41.
Zurück zum Zitat O’Callaghan FJ, et al. An epidemiological study of renal pathology in tuberous sclerosis complex. BJU Int. 2004;94(6):853–7.CrossRefPubMed O’Callaghan FJ, et al. An epidemiological study of renal pathology in tuberous sclerosis complex. BJU Int. 2004;94(6):853–7.CrossRefPubMed
42.
Zurück zum Zitat Rakowski SK, et al. Renal manifestations of tuberous sclerosis complex: incidence, prognosis, and predictive factors. Kidney Int. 2006;70(10):1777–82.CrossRefPubMed Rakowski SK, et al. Renal manifestations of tuberous sclerosis complex: incidence, prognosis, and predictive factors. Kidney Int. 2006;70(10):1777–82.CrossRefPubMed
43.
Zurück zum Zitat Ewalt DH, et al. Renal lesion growth in children with tuberous sclerosis complex. J Urol. 1998;160(1):141–5.CrossRefPubMed Ewalt DH, et al. Renal lesion growth in children with tuberous sclerosis complex. J Urol. 1998;160(1):141–5.CrossRefPubMed
44.
Zurück zum Zitat Sampson JR, et al. Renal cystic disease in tuberous sclerosis: role of the polycystic kidney disease 1 gene. Am J Hum Genet. 1997;61(4):843–51.PubMedCentralCrossRefPubMed Sampson JR, et al. Renal cystic disease in tuberous sclerosis: role of the polycystic kidney disease 1 gene. Am J Hum Genet. 1997;61(4):843–51.PubMedCentralCrossRefPubMed
45.
Zurück zum Zitat Bjornsson J, et al. Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features. Am J Pathol. 1996;149(4):1201–8.PubMedCentralPubMed Bjornsson J, et al. Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features. Am J Pathol. 1996;149(4):1201–8.PubMedCentralPubMed
46.
Zurück zum Zitat Robertson FM, et al. Renal cell carcinoma in association with tuberous sclerosis in children. J Pediatr Surg. 1996;31(5):729–30.CrossRefPubMed Robertson FM, et al. Renal cell carcinoma in association with tuberous sclerosis in children. J Pediatr Surg. 1996;31(5):729–30.CrossRefPubMed
47.
Zurück zum Zitat Washecka R, Hanna M. Malignant renal tumors in tuberous sclerosis. Urology. 1991;37(4):340–3.CrossRefPubMed Washecka R, Hanna M. Malignant renal tumors in tuberous sclerosis. Urology. 1991;37(4):340–3.CrossRefPubMed
48.
Zurück zum Zitat Clarke A, et al. End-stage renal failure in adults with the tuberous sclerosis complex. Nephrol Dial Transplant. 1999;14(4):988–91.CrossRefPubMed Clarke A, et al. End-stage renal failure in adults with the tuberous sclerosis complex. Nephrol Dial Transplant. 1999;14(4):988–91.CrossRefPubMed
49.
Zurück zum Zitat Dixon BP, Hulbert JC, Bissler JJ. Tuberous sclerosis complex renal disease. Nephron Exp Nephrol. 2011;118(1):e15–e20.CrossRefPubMed Dixon BP, Hulbert JC, Bissler JJ. Tuberous sclerosis complex renal disease. Nephron Exp Nephrol. 2011;118(1):e15–e20.CrossRefPubMed
50.
Zurück zum Zitat Bridle KR, et al. Lack of efficacy of mTOR inhibitors and ACE pathway inhibitors as antifibrotic agents in evolving and established fibrosis in Mdr2 mice. Liver Int. 2014 Feb 11. doi:10.1111/liv.12494. Epub ahead of print. Bridle KR, et al. Lack of efficacy of mTOR inhibitors and ACE pathway inhibitors as antifibrotic agents in evolving and established fibrosis in Mdr2 mice. Liver Int. 2014 Feb 11. doi:10.1111/liv.12494. Epub ahead of print.
51.
Zurück zum Zitat Rothermundt C, Gillessen S. Angioedema in a patient with renal cell cancer treated with everolimus in combination with an angiotensin-converting enzyme inhibitor. J Clin Oncol. 2013;31(5):e57–8.CrossRefPubMed Rothermundt C, Gillessen S. Angioedema in a patient with renal cell cancer treated with everolimus in combination with an angiotensin-converting enzyme inhibitor. J Clin Oncol. 2013;31(5):e57–8.CrossRefPubMed
52.
Zurück zum Zitat Bissler JJ, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013;381(9869):817–24.CrossRefPubMed Bissler JJ, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013;381(9869):817–24.CrossRefPubMed
53.
Zurück zum Zitat Hancock E, Osborne J. Lymphangioleiomyomatosis: a review of the literature. Respir Med. 2002;96(1):1–6.CrossRefPubMed Hancock E, Osborne J. Lymphangioleiomyomatosis: a review of the literature. Respir Med. 2002;96(1):1–6.CrossRefPubMed
55.
56.
Zurück zum Zitat Li C, et al. Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med. 2014;211(1):15–28.PubMedCentralCrossRefPubMed Li C, et al. Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med. 2014;211(1):15–28.PubMedCentralCrossRefPubMed
57.
Zurück zum Zitat Astrinidis A, et al. Mutational analysis of the tuberous sclerosis gene TSC2 in patients with pulmonary lymphangioleiomyomatosis. J Med Genet. 2000;37(1):55–7.PubMedCentralCrossRefPubMed Astrinidis A, et al. Mutational analysis of the tuberous sclerosis gene TSC2 in patients with pulmonary lymphangioleiomyomatosis. J Med Genet. 2000;37(1):55–7.PubMedCentralCrossRefPubMed
58.
Zurück zum Zitat Karbowniczek M, et al. Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med. 2003;167(7):976–82.CrossRefPubMed Karbowniczek M, et al. Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med. 2003;167(7):976–82.CrossRefPubMed
60.
Zurück zum Zitat Yao J, et al. Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2014;190(11):1273–82.CrossRefPubMed Yao J, et al. Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2014;190(11):1273–82.CrossRefPubMed
62.
Zurück zum Zitat Krueger DA, Northrup H. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013;49(4):255–65.PubMedCentralCrossRefPubMed Krueger DA, Northrup H. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013;49(4):255–65.PubMedCentralCrossRefPubMed
63.
Zurück zum Zitat Salerno AE, et al. Vascular involvement in tuberous sclerosis. Pediatr Nephrol. 2010;25(8):1555–61.CrossRefPubMed Salerno AE, et al. Vascular involvement in tuberous sclerosis. Pediatr Nephrol. 2010;25(8):1555–61.CrossRefPubMed
64.
Zurück zum Zitat Napolioni V, Moavero R, Curatolo P. Recent advances in neurobiology of Tuberous Sclerosis Complex. Brain Dev. 2009;31(2):104–13.CrossRefPubMed Napolioni V, Moavero R, Curatolo P. Recent advances in neurobiology of Tuberous Sclerosis Complex. Brain Dev. 2009;31(2):104–13.CrossRefPubMed
65.
Zurück zum Zitat Cappellano AM, et al. Successful everolimus therapy for SEGA in pediatric patients with tuberous sclerosis complex. Childs Nerv Syst. 2013;29(12):2301–5.CrossRefPubMed Cappellano AM, et al. Successful everolimus therapy for SEGA in pediatric patients with tuberous sclerosis complex. Childs Nerv Syst. 2013;29(12):2301–5.CrossRefPubMed
66.
Zurück zum Zitat Ouyang T, et al. Subependymal giant cell astrocytoma: current concepts, management, and future directions. Childs Nerv Syst. 2014;30(4):561–70.CrossRefPubMed Ouyang T, et al. Subependymal giant cell astrocytoma: current concepts, management, and future directions. Childs Nerv Syst. 2014;30(4):561–70.CrossRefPubMed
67.
Zurück zum Zitat Kaplan B, Qazi Y, Wellen JR. Strategies for the management of adverse events associated with mTOR inhibitors. Transplant Rev. 2014 Jul;28(3):126–33. doi:10.1016/j.trre.2014.03.002. Epub 2014 Mar 12. Kaplan B, Qazi Y, Wellen JR. Strategies for the management of adverse events associated with mTOR inhibitors. Transplant Rev. 2014 Jul;28(3):126–33. doi:10.1016/j.trre.2014.03.002. Epub 2014 Mar 12.
Metadaten
Titel
Tuberous Sclerosis Complex: new criteria for diagnostic work-up and management
verfasst von
Sharon Samueli
Klaus Abraham
Anastasia Dressler
Gudrun Groeppel
Constanze Jonak
Angelika Muehlebner
Daniela Prayer
Andreas Reitner
Univ. Prof. Dr. Martha Feucht
Pädiatrisches TSC-Zentrum Wien
Publikationsdatum
01.08.2015
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 15-16/2015
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-015-0758-y

Weitere Artikel der Ausgabe 15-16/2015

Wiener klinische Wochenschrift 15-16/2015 Zur Ausgabe

mitteilungen der gesellschaft

ÖGIM FLIP